Foghorn Therapeutics Inc.
FHTX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.81 | 0.94 | 0.00 | 0.24 |
| FCF Yield | -7.10% | -10.46% | -8.46% | -3.66% |
| EV / EBITDA | -14.43 | -9.20 | -11.92 | -24.41 |
| Quality | ||||
| ROIC | -13.64% | -11.66% | -5.99% | -9.16% |
| Gross Margin | 88.09% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.19 | 1.17 | 1.27 | 1.26 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.03% | 3.62% | 4.47% | 5.54% |
| Free Cash Flow Growth | 12.39% | 4.01% | -17.28% | 16.59% |
| Safety | ||||
| Net Debt / EBITDA | 2.94 | 1.19 | 0.79 | 0.80 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -332.20 | 0.00 | 0.00 | 0.00 |